Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma

Long-term outcomes of frontline ⁹⁰Y-ibritumomab tiuxetan in marginal zone lymphoma

Research output: Contribution to journal › Letter

@article{7ad8bc561b854c118280120b9192287d,

title = "Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma",

author = "Izidore Lossos and Reis, {Isildinha M.} and Rosenblatt, {Joseph D.} and Alderuccio, {Juan Pablo}",

year = "2020",

doi = "10.1080/10428194.2020.1802449",

language = "English (US)",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma

AU - Lossos, Izidore

AU - Reis, Isildinha M.

AU - Rosenblatt, Joseph D.

AU - Alderuccio, Juan Pablo

PY - 2020

Y1 - 2020

UR - http://www.scopus.com/inward/record.url?scp=85089105202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089105202&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1802449

DO - 10.1080/10428194.2020.1802449

M3 - Letter

AN - SCOPUS:85089105202

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -